Global Information
회사소개 | 문의 | 비교리스트

신경병증성 통증 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2020-2030년)

Neuropathic Pain Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

리서치사 Transparency Market Research
발행일 2020년 06월 상품 코드 953645
페이지 정보 영문 238 Pages
가격
US $ 5,795 ₩ 6,831,000 PDF (Single User License)
US $ 8,795 ₩ 10,367,000 PDF (Multi-user License)
US $ 11,795 ₩ 13,903,000 PDF (Corporate License)


신경병증성 통증 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2020-2030년) Neuropathic Pain Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030
발행일 : 2020년 06월 페이지 정보 : 영문 238 Pages

세계의 신경병증성 통증 치료 시장을 조사했으며, 시장 개요, 약제 클래스별, 증상별, 투여 경로별, 유통 채널별, 지역별 분석과 예측, 경쟁 상황, 기업 개요 등의 정보를 제공합니다.

목차

제1장 서문

제2장 가정과 조사 방법

제3장 주요 요약

제4장 시장 개요

  • 서론과 개요
  • 제품 개요
  • 시장 역학
    • 성장 촉진요인
    • 성장 저해요인
    • 시장 기회
  • 시장 분석과 예측

제5장 시장 전망

  • 파이프라인 분석
  • 치료 가이드라인
  • COVID-19 팬데믹의 영향

제6장 약제 클래스별 시장 분석과 예측

  • 서론과 정의
  • 시장 가치 예측
    • 항경련제
    • 항우울제
    • NSAID
    • 오피오이드
    • 스테로이드
    • 기타
  • 시장 매력 분석

제7장 증상별 시장 분석과 예측

  • 서론과 정의
  • 시장 가치 예측
    • 당뇨병성 신경병증
    • 대상포진후 신경통
    • 암 관련 통증
    • 척수 손상
    • 기타
  • 시장 매력 분석

제8장 투여 경로별 시장 분석과 예측

  • 서론과 정의
  • 시장 가치 예측
    • 경구 투여
    • 국소 투여
    • 기타
  • 시장 매력 분석

제9장 유통 채널별 시장 분석과 예측

  • 서론과 정의
  • 시장 가치 예측
    • 병원 약국
    • 소매 약국
    • 온라인 약국
  • 시장 매력 분석

제10장 지역별 시장 분석과 예측

  • 주요 조사 결과
  • 시장 가치 예측
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장 매력 분석

제11장 북미 시장 분석과 예측

  • 서론
  • 시장 가치 예측
    • 미국
    • 캐나다
  • 시장 매력 분석

제12장 유럽 시장 분석과 예측

제13장 아시아태평양 시장 분석과 예측

제14장 라틴아메리카 시장 분석과 예측

제15장 중동 및 아프리카 시장 분석과 예측

제16장 경쟁 상황

  • 경쟁 매트릭스
  • 시장 점유율 분석
  • 기업 개요
    • Novartis AG
    • GlaxoSmithKline plc
    • AstraZeneca
    • Pfizer, Inc.
    • Eli Lilly and Company
    • Mallinckrodt Pharmaceuticals
    • Johnson & Johnson
    • Abbott
    • Endo Pharmaceuticals, Inc.
    • Teva Pharmaceutical Industries Limited
    • Merck & Co., Inc.
KSM 20.08.31

List of Tables

  • Table 01: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
  • Table 02: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018-2030
  • Table 03: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 04: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 05: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 06: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Region, 2018-2030
  • Table 07: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
  • Table 08: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018-2030
  • Table 09: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 10: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 11: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 12: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country, 2018-2030
  • Table 13: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
  • Table 14: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018-2030
  • Table 15: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 16: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 17: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 18: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 19: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
  • Table 20: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018-2030
  • Table 21: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 22: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 23: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 24: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 25: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
  • Table 26: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018-2030
  • Table 27: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 28: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 29: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 30: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 31: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
  • Table 32: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018-2030
  • Table 33: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 34: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 35: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 36: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030

List of Figures

  • Figure 01: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) and Distribution (%), by Region, 2019 and 2030
  • Figure 02: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, 2018-2030
  • Figure 03: Market Value Share, by Drug Class, 2019
  • Figure 04: Market Value Share, by Disease Type, 2019
  • Figure 05: Market Value Share, by Route of Administration, 2019
  • Figure 06: Market Value Share, by Distribution Channel, 2019
  • Figure 07: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030
  • Figure 08: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anticonvulsants, 2018-2020
  • Figure 09: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antidepressants, 2018-2020
  • Figure 10: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by NSAIDs, 2018-2020
  • Figure 11: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Opioids, 2018-2020
  • Figure 12: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Steroids, 2018-2020
  • Figure 13: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2018-2020
  • Figure 14: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020-2030
  • Figure 15: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 16: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diabetic Neuropathy, 2018-2020
  • Figure 17: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Post-herpetic Neuralgia, 2018-2020
  • Figure 18: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cancer-related Pain, 2018-2020
  • Figure 19: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Spinal Cord Injury, 2018-2020
  • Figure 20: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2018-2020
  • Figure 21: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 22: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 23: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2018-2020
  • Figure 24: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Topical, 2018-2020
  • Figure 25: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2018-2020
  • Figure 26: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 27: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 28: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2018-2030
  • Figure 29: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2018-2030
  • Figure 30: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2018-2030
  • Figure 31: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 32: Global Neuropathic Pain Therapeutics Market, by Region, 2019 and 2030
  • Figure 33: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Region, 2020-2030
  • Figure 34: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 35: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030
  • Figure 36: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020-2030
  • Figure 37: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 38: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 39: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 40: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 41: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 42: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 43: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Country, 2019 and 2030
  • Figure 44: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country, 2020-2030
  • Figure 45: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 46: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030
  • Figure 47: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020-2030
  • Figure 48: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 49: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 50: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 51: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 52: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 53: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 54: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
  • Figure 55: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 56: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 57: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030
  • Figure 58: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020-2030
  • Figure 59: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 60: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 61: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 62: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 63: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 64: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 65: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
  • Figure 66: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 67: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 68: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030
  • Figure 69: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020-2030
  • Figure 70: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 71: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 72: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 73: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 74: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 75: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 76: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
  • Figure 77: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 78: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 79: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030
  • Figure 80: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020-2030
  • Figure 81: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 82: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 83: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 84: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 85: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 86: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 87: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
  • Figure 88: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020-2030

Title:
Neuropathic Pain Therapeutics Market (Drug Class: Anticonvulsants, Antidepressants, NSAIDs, Opioids, Steroids, and Others; Indication: Diabetic Neuropathy, Post-herpetic Neuralgia, Cancer-related Pain, Spinal Cord Injury, and Others; Route of Administration: Oral, Topical, and Others; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030.

Scope of the Report

TMR's report on the global neuropathic pain therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the revenue of the global neuropathic pain therapeutics market for the period 2018-2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global neuropathic pain therapeutics market from 2020 to 2030.

The report has been prepared after extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global neuropathic pain therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various attributes of the global neuropathic pain therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global neuropathic pain therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global neuropathic pain therapeutics market.

The report also delves into the competition landscape of the global neuropathic pain therapeutics market. Key players operating in the global neuropathic pain therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global neuropathic pain therapeutics market that have been profiled in this report.

Key Questions Answered:

  • What is the sales/revenue generated by neuropathic pain drugs across all regions during the forecast period?
  • What are the opportunities in the global neuropathic therapeutics pain market?
  • What are the major drivers, restraints, opportunities, and threats in the global market?
  • Which region is set to expand at the fastest CAGR during the forecast period?
  • Which indication segment is expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Research Objectives and Research Approach

The comprehensive report on the global neuropathic pain therapeutics market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that have been appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global neuropathic pain therapeutics market in terms of drug class, disease type, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2030 has been provided. Such valuable insights enable market stakeholders to make informed business decisions for investment in the global neuropathic pain therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Neuropathic Pain Therapeutics Market

4. Market Overview

  • 4.1. Introduction & Overview
  • 4.2. Product Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, 2018-2030

5. Market Outlook

  • 5.1. Pipeline Analysis
  • 5.2. Treatment Guidelines
  • 5.3. COVID-19 Pandemics Impact on Industry

6. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
    • 6.2.1. Anticonvulsants
    • 6.2.2. Antidepressants
      • 6.2.2.1. Tricyclic Antidepressants
      • 6.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
    • 6.2.3. NSAIDs
    • 6.2.4. Opioids
    • 6.2.5. Steroids
    • 6.2.6. Others
  • 6.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class

7. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Indication

  • 7.1. Introduction & Definition
  • 7.2. Global Neuropathic Pain Therapeutics Market Value (US$) Forecast, by Indication, 2018-2030
    • 7.2.1. Diabetic Neuropathy
    • 7.2.2. Post-herpetic Neuralgia
    • 7.2.3. Cancer-related Pain
    • 7.2.4. Spinal Cord Injury
    • 7.2.5. Others
  • 7.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication

8. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Global Neuropathic Pain Therapeutics Market Value (US$) Forecast, by Route of Administration, 2018-2030
    • 8.2.1. Oral
    • 8.2.2. Topical
    • 8.2.3. Others
  • 8.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration

9. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction & Definition
  • 9.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
    • 9.2.1. Hospital Pharmacies
    • 9.2.2. Retail Pharmacies
    • 9.2.3. Online Pharmacies
  • 9.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel

10. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Region

11. North America Neuropathic Pain Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
    • 11.2.1. Anticonvulsants
    • 11.2.2. Antidepressants
      • 11.2.2.1. Tricyclic Antidepressants
      • 11.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
    • 11.2.3. NSAIDs
    • 11.2.4. Opioids
    • 11.2.5. Steroids
    • 11.2.6. Others
  • 11.3. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018-2030
    • 11.3.1. Diabetic Neuropathy
    • 11.3.2. Post-herpetic Neuralgia
    • 11.3.3. Cancer-related Pain
    • 11.3.4. Spinal Cord Injury
    • 11.3.5. Others
  • 11.4. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
    • 11.4.1. Oral
    • 11.4.2. Topical
    • 11.4.3. Others
  • 11.5. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. North America Neuropathic Pain Therapeutics Market Attractiveness Analysis
    • 11.7.1. By Drug Class
    • 11.7.2. By Indication
    • 11.7.3. By Route of Administration
    • 11.7.4. By Distribution Channel
    • 11.7.5. By Country

12. Europe Neuropathic Pain Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
    • 12.2.1. Anticonvulsants
    • 12.2.2. Antidepressants
      • 12.2.2.1. Tricyclic Antidepressants
      • 12.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
    • 12.2.3. NSAIDs
    • 12.2.4. Opioids
    • 12.2.5. Steroids
    • 12.2.6. Others
  • 12.3. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018-2030
    • 12.3.1. Diabetic Neuropathy
    • 12.3.2. Post-herpetic Neuralgia
    • 12.3.3. Cancer-related Pain
    • 12.3.4. Spinal Cord Injury
    • 12.3.5. Others
  • 12.4. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
    • 12.4.1. Oral
    • 12.4.2. Topical
    • 12.4.3. Others
  • 12.5. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis
    • 12.7.1. By Drug Class
    • 12.7.2. By Indication
    • 12.7.3. By Route of Administration
    • 12.7.4. By Distribution Channel
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Neuropathic Pain Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
    • 13.2.1. Anticonvulsants
    • 13.2.2. Antidepressants
      • 13.2.2.1. Tricyclic Antidepressants
      • 13.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
    • 13.2.3. NSAIDs
    • 13.2.4. Opioids
    • 13.2.5. Steroids
    • 13.2.6. Others
  • 13.3. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018-2030
    • 13.3.1. Diabetic Neuropathy
    • 13.3.2. Post-herpetic Neuralgia
    • 13.3.3. Cancer-related Pain
    • 13.3.4. Spinal Cord Injury
    • 13.3.5. Others
  • 13.4. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
    • 13.4.1. Oral
    • 13.4.2. Topical
    • 13.4.3. Others
  • 13.5. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Retail Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis
    • 13.7.1. By Drug Class
    • 13.7.2. By Indication
    • 13.7.3. By Route of Administration
    • 13.7.4. By Distribution Channel
    • 13.7.5. By Country/Sub-region

14. Latin America Neuropathic Pain Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
    • 14.2.1. Anticonvulsants
    • 14.2.2. Antidepressants
      • 14.2.2.1. Tricyclic Antidepressants
      • 14.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
    • 14.2.3. NSAIDs
    • 14.2.4. Opioids
    • 14.2.5. Steroids
    • 14.2.6. Others
  • 14.3. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018-2030
    • 14.3.1. Diabetic Neuropathy
    • 14.3.2. Post-herpetic Neuralgia
    • 14.3.3. Cancer-related Pain
    • 14.3.4. Spinal Cord Injury
    • 14.3.5. Others
  • 14.4. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
    • 14.4.1. Oral
    • 14.4.2. Topical
    • 14.4.3. Others
  • 14.5. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis
    • 14.7.1. By Drug Class
    • 14.7.2. By Indication
    • 14.7.3. By Route of Administration
    • 14.7.4. By Distribution Channel
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Neuropathic Pain Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
  • 15.2. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
    • 15.2.1. Anticonvulsants
    • 15.2.2. Antidepressants
      • 15.2.2.1. Tricyclic Antidepressants
      • 15.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
    • 15.2.3. NSAIDs
    • 15.2.4. Opioids
    • 15.2.5. Steroids
    • 15.2.6. Others
  • 15.3. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018-2030
    • 15.3.1. Diabetic Neuropathy
    • 15.3.2. Post-herpetic Neuralgia
    • 15.3.3. Cancer-related Pain
    • 15.3.4. Spinal Cord Injury
    • 15.3.5. Others
  • 15.4. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
    • 15.4.1. Oral
    • 15.4.2. Topical
    • 15.4.3. Others
  • 15.5. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
    • 15.5.1. Hospital Pharmacies
    • 15.5.2. Retail Pharmacies
    • 15.5.3. Online Pharmacies
  • 15.6. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis
    • 15.7.1. By Drug Class
    • 15.7.2. By Indication
    • 15.7.3. By Route of Administration
    • 15.7.4. By Distribution Channel
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Competition Matrix
  • 16.2. Market Share Analysis, by Company, 2019
  • 16.3. Company Profiles
    • 16.3.1. Novartis AG
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Company Financials
      • 16.3.1.3. Growth Strategies
      • 16.3.1.4. SWOT Analysis
    • 16.3.2. GlaxoSmithKline plc
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Company Financials
      • 16.3.2.3. Growth Strategies
      • 16.3.2.4. SWOT Analysis
    • 16.3.3. AstraZeneca
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Company Financials
      • 16.3.3.3. Growth Strategies
      • 16.3.3.4. SWOT Analysis
    • 16.3.4. Pfizer, Inc.
      • 16.3.4.1. Company Overview (HQ, Business Segments)
      • 16.3.4.2. Company Financials
      • 16.3.4.3. Growth Strategies
      • 16.3.4.4. SWOT Analysis
    • 16.3.5. Eli Lilly and Company
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Company Financials
      • 16.3.5.3. Growth Strategies
      • 16.3.5.4. SWOT Analysis
    • 16.3.6. Mallinckrodt Pharmaceuticals
      • 16.3.6.1. Company Overview (HQ, Business Segments)
      • 16.3.6.2. Company Financials
      • 16.3.6.3. Growth Strategies
      • 16.3.6.4. SWOT Analysis
    • 16.3.7. Johnson & Johnson
      • 16.3.7.1. Company Overview (HQ, Business Segments)
      • 16.3.7.2. Company Financials
      • 16.3.7.3. Growth Strategies
      • 16.3.7.4. SWOT Analysis
    • 16.3.8. Abbott
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Company Financials
      • 16.3.8.3. Growth Strategies
      • 16.3.8.4. SWOT Analysis
    • 16.3.9. Endo Pharmaceuticals, Inc.
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Company Financials
      • 16.3.9.3. Growth Strategies
      • 16.3.9.4. SWOT Analysis
    • 16.3.10. Teva Pharmaceutical Industries Limited
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Company Financials
      • 16.3.10.3. Growth Strategies
      • 16.3.10.4. SWOT Analysis
    • 16.3.11. Merck & Co., Inc.
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Company Financials
      • 16.3.11.3. Growth Strategies
      • 16.3.11.4. SWOT Analysis
Back to Top
전화 문의
F A Q